Quantcast
 
Annual return of 118.79% - See How  Click here now!


 

Cubist Pharmaceuticals to Announce Third Quarter 2008 Financial Results on Thursday, October 16, 2008

Thu. October 02, 2008; Posted: 11:55 AM
Stocks RSS
LEXINGTON, Mass., Oct 02, 2008 (BUSINESS WIRE) -- CBST | Quote | Chart | News | PowerRating -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST | Quote | Chart | News | PowerRating) will issue its third quarter 2008 financial results at 4:00 p.m. EDT on Thursday, October 16th, 2008. In connection with this announcement, Cubist will host a conference call and live audio webcast (with slides) at 5:00 p.m. EDT that same day to discuss its third quarter financial results, business activities and financial outlook.

As always, the quarterly earnings call will be available via phone and webcast. The phone call dial-in information is listed below. To access the webcast, please log on to the Cubist website at www.cubist.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available on Cubist's website beginning approximately three hours after the call.

CONFERENCE CALL & WEBCAST INFORMATION

Cubist will host a conference call and live audio webcast to discuss its third quarter 2008

financial results, business activities and financial outlook.

WHEN: Thursday, October 16, 2008 at 5:00 p.m. EDT

LIVE DOMESTIC & CANADA CALL-IN: 877-407-0778

LIVE INTERNATIONAL CALL-IN: 201-689-8565

24-HOUR REPLAY DOMESTIC & CANADA: 877-660-6853

24-HOUR REPLAY INTERNATIONAL: 201-612-7415

REPLAY PASSCODES (BOTH REQUIRED FOR PLAYBACK):

ACCOUNT #: 286 CONFERENCE ID #: 295809

CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT: www.cubist.com

Replay will be available for 30 days at www.cubist.com

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives calledlipopeptides. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase II clinical trials for the prevention of blood loss during cardiothoracic surgery, and pre-clinical programs that address unmet medical needs in Gram-positive infections, Gram-negative infections, CDAD (Clostridium difficile-associated diarrhea), and HCV (Hepatitis C infections). Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

SOURCE: Cubist Pharmaceuticals, Inc.

Cubist Pharmaceuticals, Inc. Eileen C. McIntyre, 781-860-8533 Senior Director, Corporate Communications eileen.mcintyre@cubist.com

For full details on Cubist Pharmaceuticals (CBST) click here. Cubist Pharmaceuticals (CBST) has Short Term PowerRatings of 8. Details on Cubist Pharmaceuticals (CBST) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2008 The Connors Group, Inc.